Most Patients With Atrial Fibrillation Do Not Have Current Indication for SGLT2 Inhibitors - The Cardiology Advisor

A study was conducted to assess the relationship between SGLT2i-eligibility and cardiovascular events in patients with atrial fibrillation.

A majority of patients with atrial fibrillation (AF) do not have an indication for sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy but have a substantial risk for cardiovascular events, ac… [+4055 chars]

full article...